EUVIMEDEUVIMED entdecken
Crossref

Brief of over 300 reproductive health researchers as Amici Curiae in FDA v. Alliance for Hippocratic Medicine

Amanda Barrow, Cathren Cohen, Jaclyn Serpico, Melissa Goodman, Daniel Grossman, Sarah Raifman, Ushma Upadhyay

Perspectives on Sexual and Reproductive Health · 2024

DOI: 10.1111/psrh.12281 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Perspectives on Sexual and Reproductive Health, 2024. Verfasst von Amanda Barrow und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of California Los Angeles Center on Reproductive Health, Law, and Policy, Los Angeles, California, USA. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Mifepristone. Die Arbeit nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

On January 30, 2024, over 300 researchers filed an amicus brief in FDA v. Alliance for Hippocratic Medicine , a United States (US) Supreme Court case that could have severely impacted access to mifepristone, one of the two drugs commonly used in medication abortion. The researchers summarize the legal challenges to the US Food and Drug Administration's (FDA's) original approval of mifepristone in 2000 and its 2016 and 2021 decisions modifying mifepristone's Risk Evaluation and Mitigation Strategy (REMS) Program and label, the responses from the FDA and drug manufacturer to the challenges, and the potential implications of the Court's decision on access to mifepristone in the US. The researchers detail how the FDA relied on a robust scientific record analyzing tens of thousands of patient experiences that conclusively demonstrated the safety and effectiveness of the changes to the mifepristone REMS Program and label and urge the Supreme Court to rely on the clear scientific record and preserve access to mifepristone without reimposing restrictions. What follows is a reprint of this brief.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

United States Food and Drug AdministrationMifepristoneHumansUnited StatesAbortion, InducedFemaleSupreme Court DecisionsPregnancyDrug ApprovalReproductive HealthAbortifacient Agents, SteroidalRisk Evaluation and Mitigation

Stichwörter der Autor:innen

FDAREMSabortionlaw/legal issuesmifepristone

Substanzen

MifepristoneAbortifacient Agents, Steroidal

Autor:innen und Institutionen

  • University of California Los Angeles Center on Reproductive Health, Law, and Policy, Los Angeles, California, USA.
  • Advancing New Standards in Reproductive Health, Department of Obstetrics, Gynecology, & Reproductive Sciences, University of California San Francisco, Oakland, California, USA.

Zitieren

APA

Barrow, A., Cohen, C., Serpico, J., Goodman, M., Grossman, D., Raifman, S., & Upadhyay, U. (2024). Brief of over 300 reproductive health researchers as Amici Curiae in FDA v. Alliance for Hippocratic Medicine. Perspectives on Sexual and Reproductive Health. https://doi.org/10.1111/psrh.12281

Vancouver

Barrow A, Cohen C, Serpico J, Goodman M, Grossman D, Raifman S, et al. Brief of over 300 reproductive health researchers as Amici Curiae in FDA v. Alliance for Hippocratic Medicine. Perspectives on Sexual and Reproductive Health. 2024. doi:10.1111/psrh.12281

BibTeX
@article{Barrow2024,
  author = {Barrow, Amanda and Cohen, Cathren and Serpico, Jaclyn and Goodman, Melissa and Grossman, Daniel and Raifman, Sarah and Upadhyay, Ushma},
  title = {Brief of over 300 reproductive health researchers as Amici Curiae in FDA v. Alliance for Hippocratic Medicine},
  journal = {Perspectives on Sexual and Reproductive Health},
  year = {2024},
  doi = {10.1111/psrh.12281}
}
Kostenlos starten →